TY - JOUR ID - 241522 TI - Evaluation of Safety of Nortriptyline in Patients with Chronic Obstructive Pulmonary Disease JO - TANAFFOS (Respiration) JA - RSPR LA - en SN - 1735-0344 AU - Golshan, Mohamad AU - Roushan-Zamir, Tooraj AU - Sherkat Masoom, Moulood AU - Asadian, Asadolah AD - Department of Pulmonary Medicine, Isfahan University of Medical Sciences and Health Services, ISFAHAN-IRAN AD - epartment of Pulmonary Medicine, Isfahan University of Medical Sciences and Health Services, ISFAHAN-IRAN Y1 - 2003 PY - 2003 VL - 2 IS - 4(autumn) SP - 41 EP - 48 KW - Chronic Obstructive Pulmonary Disease (COPD) KW - Depression KW - Tricyclic antidepressant(s) KW - Nortriptyline DO - N2 - Background: Patients with severe chronic obstructive pulmonary disease (COPD) have a poor quality of life and limited life expectancy, frequently resulting in depression that enhances their symptoms. This depressive state might need medical intervention; however, the safety of antidepressant drugs in these patients with poor respiratory function is not clear. Materials and Methods: Thirty-four subjects with concomitant COPD and depression as well as 34 controls with COPD without depression were enrolled in a single blind controlled study. Nortriptyline was prescribed to the first group and placebo to the second. Spirometric and gas analysis findings were compared before and after a three-month course of trial. Results: Pulmonary function tests and gas analysis recordings did not show any deterioration after nortriptyline administration. Two deaths occurred during the study period, one in study group due to respiratory infection and the second in control group because of Pulmonary Thromboembolism (PTE). Conclusion: Nortriptyline is a safe medication to be used in COPD patients when indicated. (Tanaffos 2003; 2(8): 41-48) UR - https://www.tanaffosjournal.ir/article_241522.html L1 - https://www.tanaffosjournal.ir/article_241522_4ec27221d2d27ca7f910fd6298d2e162.pdf ER -